The % of patients alive bodes well for the long term follow-up on patients. To deflate the good news, the skeptics are making some hefty assumptions that every single failed screen patients is dead. We don’t know how many are alive from that failed the main arm of the trial, but we do know that number is not ZERO. Consider that we know the compassionate use arm had approximately 10 patients who also remained alive (they are part of the failed screened group). We also know that among the failed screen group includes the Psuedo arm (the patients who historically show the greatest signs of Radiation and Temodar working well) which have a high likelihood of having long term survival (regardless of which cohort they would be: vaccine or placebo). Therefore to have the skeptics make the assumption that the long term survival percentage wouldn’t improve by a decent percentage outside the main arm is at best a faulty one. They can’t stop hanging around and trying to diminishing the main arm survival. And they do so by pretending there is no long term survival outside the main arm, which just isn’t true.
Market Data 
Markets 
AI
